Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CENPE | Q02224 | 2/20 | 0.34 |
| ▸ | WDR5 | P61964 | 2/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477414 | 0.92 | PREP (0.37) | AKR1B1CENPEWDR5SMN1; SMN2 | |
| SCHEMBL4489713 | 0.90 | CCR2 (0.38) | P2RX7AKR1B1WDR5EZH2FSCN1 | |
| SCHEMBL4477879 | 0.90 | MEN1 (0.38) | P2RX7AKR1B1FSCN1SMN1; SMN2 | |
| SCHEMBL31060990 | 0.89 | AKR1B1 (0.36) | AKR1B1CENPEWDR5MAPK1FSCN1 | |
| SCHEMBL4479511 | 0.89 | AKR1B1 (0.36) | AKR1B1CENPEWDR5MAPK1FSCN1 | |
| SCHEMBL4488414 | 0.88 | AKR1B1 (0.35) | AKR1B1CENPEWDR5MAPK1FSCN1 | |
| SCHEMBL4484112 | 0.87 | LMNA (0.36) | P2RX7AKR1B1SMN1; SMN2 | |
| SCHEMBL4477518 | 0.86 | GAA (0.42) | SMN1; SMN2 | |
| SCHEMBL4482091 | 0.86 | FSCN1 (0.34) | P2RX7AKR1B1WDR5FSCN1SMN1; SMN2 | |
| SCHEMBL4482140 | 0.84 | P2RX7 (0.39) | P2RX7WDR5EZH2SMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087767-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | P2RX7 3818/4885AKR1B1 2248/4885CENPE 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.